Home » FightingDrugFailure » Partner Sites » Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology (IKP) » Positions Offered

IKP had offered the following positions from September 2010 to September 2013. The projects have now been finished and the results have been published.

Novel Predictive Markers for Tamoxifen Outcome in Early Breast Cancer

Starting date: Spring 2010
Duration: 3 years

This project will link up with the current developments of a relationship of CYP2D6 genetic variants as predictors of tamoxifen outcome and explore novel putative treatment predictors of breast cancer. Through candidate approaches, the project utilizes well characterized patient cohorts (patients with endocrine treatment) for the identification of putative treatment predictors which will be further investigated for their mechanistic role in treatment efficacy. The project aims towards the translation of basic molecular findings into the clinical application.

Leading Scientist: Prof. H. Brauch


The Role of Epigenetics in Breast Cancer Prognosis and Treatment Outcome

Starting date: Fall 2010
Duration: 3 years

The project will investigate the role of methylation patterns and micro RNAs of breast tumors on the patient’s prognosis and treatment outcome. Through candidate approaches the project utilizes tumor tissues from well characterized patient cohorts (chemotherapy, taxane therapy) for the identification of putative treatment predictors. The project explores the clinical relevance of epigenetic principles in breast cancer for the identification of novel drug targets.

Leading Scientist: Prof. H. Brauch


The Role of Transporters in Pharmacogenomics

Starting date: Spring 2010
Duration: 3 years

Transporters play critical roles in the absorption, disposition, and elimination of numerous drugs that are in clinical use. Alterations in the expression and function of these transporters may significantly contribute to drug pharmacokinetics and the interindividual variability of drug response. This project aims to unravel genetic and non-genetic factors that affect transporter expression and function. The long-term goal is to explore the impact of transporter Pharmacogenomics in disease cohorts already available at the Institute of Clinical Pharmacology.

Leading Scientist: Prof. Dr. A. Nies


Pharmacogenomics of Cancer Drug Metabolism in Human Liver

Starting date: Fall 2010
Duration: 3 years

The goal of this project is to identify and validate novel relationships between genomic determinants and drug biotransformation capacity. It builds up upon a previously established large human liver bank with extensive patient documentation and analytical characterization including drug metabolizing enzyme expression and function and genome-wide gene expression and SNP data. Besides standard molecular biology laboratory work the project requires an interest and skills in bioinformatics and data mining tools.

Leading Scientists: Prof. M. Schwab, Prof. Dr. U. Zanger